Risk factors for drug-induced liver injury in people with HIV on anti-tuberculosis treatment
Pedro Martínez-Ayala(Hospital Civil de Guadalajara), Jaime Federico Andrade-Villanueva(Universidad de Guadalajara), Fernando Amador-Lara(Universidad de Guadalajara), Moisés Salgado-de la Mora(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Christian Gerardo Alfaro-Rivera(Hospital Civil de Guadalajara), J.M. Aldana-Ledesma(Hospital Civil de Guadalajara), Vida Verónica Ruíz-Herrera(Hospital Civil de Guadalajara), Paulina Alejandra Sánchez-Álvarez(Hospital Civil de Guadalajara), José Antonio Velarde-Ruiz Velasco(Hospital Civil de Guadalajara), Sergio Zuñiga-Quiñonez(Cornell University), Guillermo Adrián Alanis-Sánchez(Universidad de Guadalajara), Luz Alicia González-Hernández(Universidad de Guadalajara)
Enfermedades infecciosas y microbiologia clinica (English ed )
May 1, 2026
Cited by 0
Related Papers
Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
|The Lancet Respiratory Medicine|2021|225
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies
|Science Translational Medicine|2017|169
Oral Manifestations Associated with HIV/AIDS Patients
|Medicina|2022|97